RxDoctor Payments Data

Ghassan Sayegh, DO

Gastroenterology · Yonkers, NYNPI 1164874186

Payments from drug & device makers

$35,976in general payments, 2019–2025

Across 300 payments — averaging $119.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$30K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$877
  • Phathom Pharmaceuticals, Inc.$628
  • QOL Medical, LLC$536
  • Ardelyx, Inc.$459
  • plus $2K from 18 others

What the payments were for

  • Speaking & faculty fees$28,73880%
  • Travel & lodging$750%
  • Food & beverage$7,16320%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$35,976 in reported general payments places this provider in the 85th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York

Medicare billing

Part B allowed, 2024
$81,030
Medicare patients
243
Services billed
488

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide160$100,375
CreonLipase/Protease/Amylase40$71,169
VoqueznaVonoprazan Fumarate37$26,486
TrulancePlecanatide15$10,387
CholestyramineCholestyramine (With Sugar)34$3,348
Pantoprazole Sodium287$1,582
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates29$1,456
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl90$1,193
Cholestyramine LightCholestyramine12$644
Sucralfate15$632
Famotidine54$506
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl30$476
Dicyclomine Hcl18$427
Omeprazole70$421
Hydrocortisone14$102

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$30,330$171,543200 claims
Phathom Pharmaceuticals, Inc.Voquezna$628$26,48637 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$1,173$10,38715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in Yonkers

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →